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Abstract
In the present study we examined the structural integrity of the myelin sheath in the peripheral nerves from short-term
streptozotocin (STZ)-treated diabetic rats, using ESR spectroscopy as a tool in determining the dynamic state and the
structure of the myelin lipid phase. Experiments were performed on spin-labeled sciatic and sural nerves from STZ-treated
Hannover^Wistar rats and age-matched controls. The spectrum analysis employed a numerical simulation model with the set
of fitting parameters that in the same time relate the ESR line shape and structure and dynamics of the probed environment.
The simulation considered three spectral components weighted and summed in the composite spectrum. The comparative
analysis of results showed the fraction of the spectral component II to be significantly increased in the spectra of diabetic rats,
indicating the significant increase in overall fluidity of the myelin structure. The origin of fluidity changes was further
investigated using an experimental model for demyelination (local injection of ethidium bromide in vivo), proteolytic action
of trypsin in vitro, and osmotic myelin swelling in vitro. Analysis and comparison of the results suggested a conclusion in
terms of changed biophysical properties of the myelin lipid phase in peripheral nerves in the pathology of diabetes. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
The peripheral neuropathy associated with diabe-
tes is one of the most common polyneuropathies and
at least 50% of diabetic patients will develop a form
of diabetic neuropathy within 25 years after diagno-
sis. The characteristic histopathological ¢ndings are
axonal degeneration, secondary myelin break-down
resulting in so-called secondary demyelination and
atrophy. The underlying pathological mechanisms
are unclear. However, possible factors involved are
protein glycosylation, accumulation of polyols, al-
tered lipid metabolism, decreased myo-inositol con-
tent, altered Schwann cell function, local ischemia
and lack of neurotrophic factors [1^3].
Although, as a general phenomenon, segmental
and paranodal demyelination is the feature of long-
term diabetic neuropathy, some ultrastructural
changes of the myelin sheath in early diabetes must
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not be excluded. Morphological ¢ndings in diabetic
neuropathy are associated with widespread distur-
bances of axonal membrane excitability and conse-
quently peripheral nerve dysfunction [2^4]. An early
feature of diabetic nerve damage in humans is reduc-
tion of sensory and motor nerve conduction velocity
accompanied by abnormalities in compound nerve
action potentials later associated with progressive
nerve ¢ber loss, atrophy and concomitant deteriora-
tion of neural function [4]. Our electrophysiological
studies performed on the peripheral nerves of short-
term streptozotocin (STZ)-diabetic rats, used as a
model of early diabetes, revealed signi¢cant reduc-
tion in nerve conduction velocity associated with se-
lective defects in the function of the inward recti¢er ^
speci¢cally internodal, predominantly potassium
conductance that regulates nerve excitability [5,6].
Similar functional defects are recently described in
humans [7], suggesting that beside probable structur-
al changes of ion channels (glycosylation, phosphor-
ylation), some additional ultrastructural changes in
myelin structure might occur prior to chronic demye-
linization, possibly being an early event associated
with the development of diabetic neuropathy.
In the present study we examined myelin sheaths
in the peripheral nerves from short-term streptozoto-
cin (STZ)-diabetic rats using electron spin resonance
(ESR) spectroscopy as a tool in determining changes
of myelin lipid phase ordering and dynamics. To
assess possible explanations for the changes of £uid-
ity, we applied a frequently used experimental model
for demyelination (local treatment with ethidium
bromide (EB) in vivo), as well as two simple models
for membrane £uidization (proteolytic action of tryp-
sin and osmotic stress in vitro). Both models were
analyzed using the same methodology of ESR on
the spin-labeled myelin lipid phase.
2. Materials and methods
2.1. Experimental models
Experiments were performed on STZ-treated
Hannover^Wistar male rats and age-matched con-
trols. Diabetes was induced in 3^4-weeks-old rats
(weight 90^100 g) by three consecutive injections of
STZ (45 mg/kg i.p. 3 days in the row). The rats were
weighed regularly and blood glucose levels were mea-
sured (Glucometer ELITE 3904M, Bayer) in samples
drawn from the tail vein. After 12 weeks of diabetes
animals showed marked hyperglycemia, 24.21 þ 0.98
mmol/l vs. 8.28 þ 0.66 mmol/l (mean þ S.E.M.,
n = 10) with an approximate weight loss of 30% in
diabetic animals.
Diabetic animals were killed by overdose of anes-
thetic. Sciatic and sural nerves of approximately 2 cm
length were quickly dissected out from each rat,
pinned to the bottom of the wax-coated chamber
and carefully desheathed. Isolated nerves were con-
tinuously perfused with mammalian Ringer’s solu-
tion containing in mmol/l : 127 NaCl, 1.9 KCl, 2.4
CaCl2, 1.2 KH2PO4, 1.3 MgSO4, 26 NaHCO3 and
10 glucose. After the surgical procedure was ¢nished,
the nerves were gently put into the testing capillary
tube for spin labeling.
The experiments with induced demyelination were
performed on the age-matched healthy animals, with
local injection of 1% EB in the surgically opened
right-hand side sciatic nerve. The left-hand side sci-
atic nerve served as the control. After 7 days the
animals were sacri¢ced, and the procedure of dissec-
tion and preparation for spin labeling was the same
as described previously.
The experiments with model £uidization by trypsin
were done on dissected and isolated sciatic nerves
from healthy animals. Desheathed nerves were kept
in trypsin solution (625 mg trypsin/500 ml) for 1 h at
40‡C, washed and returned to Ringer’s solution for
spin labeling afterwards.
In the experiments with changed osmotic condi-
tions, already prepared sciatic nerves were put into
hypo-osmolar (210 mmol/l) or hyper-osmolar (350
mmol/l) Ringer’s solution (osmolarity adjusted by
decreased or increased NaCl content).
2.2. Spin labeling
The prepared nerve sample was incubated (5 min)
with 6U1016 molecules of lipophilic spin probe,
methyl ester of 5-doxyl palmitate MeFASL(10,3)
(synthesized by Prof. S. Pec›ar, Faculty of Pharmacy,
University of Ljubljana, Slovenia), uniformly distrib-
uted over the walls of the glass tube. The labeled
sample was transferred into a glass capillary (1 mm
inner diameter) and the ESR spectrum immediately
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recorded on a Bruker 300 spectrometer (P = 10 mW,
f = 9.3 GHz), at 37‡C.
2.3. ESR line shape evaluation
The ESR spectrum of lipid spin probe incorpo-
rated in the lipid bilayer can be calculated using
the spin Hamiltonian, in which the organization
and dynamics of neighboring molecules are consid-
ered to partially average the components of the in-
teraction tensors. The formalism for the calculation
of the spectrum was performed according to the
model developed by Schindler and Seelig [8]. This
model provides a set of ¢tting parameters that in
the same time relate to the ESR line shape and re£ect
the structure and dynamics of the probed environ-
ment. Using the appropriate set of parameters, one
can produce an ESR spectrum s(B) (B-magnetic
¢eld):
sB  sS1;S3; d 20; d 22;B 1
The order parameters S3 and S1 describe the average
amplitude of motion (or time-averaged position) of
the long molecular axis of the nitrogen 2pZ orbital,
relative to the bilayer normal and perpendicular to
the bilayer normal, respectively, while rotational cor-
relation times d22 and d20 refer to the rotation around
and perpendicular to the long molecular axis of the
spin label, respectively.
In applying the model to the analysis of the com-
plex myelin sheath spectra, we found that a reason-
ably good ¢t could be obtained employing three typ-
ical spectral components si(B), calculated using Eq.
1, weighted and summed in the composite spectrum
S(B).
SB 
X
wisiB 2
X
wi  1 3
The weighting factor wi of a component si(B) repre-
sents its relative contribution to the whole spectrum.
The weighting factors of the spectral components in
the composite calculated spectrum (that is to ¢t the
experimental one), could be computed by the linear
least squares approach in which the optimal values
of wi are evaluated through the maximum likelihood
of the least squares merit function. The goodness of
¢t was deduced from the M2-value.
3. Results
3.1. ESR spectra of myelin sheath lipid phase
The lipophilic spin probe MeFASL(10,3) incorpo-
rated into the lipid rich myelin sheath of prepared
nerve samples obtained from SZT-induced diabetic
rats as well as control animals, enabled us to record
the respective ESR spectra. The spectra were stable,
indicating that there was no reduction of the NO
moiety to the EPR silent form that could have taken
place if the probes penetrated into the interior of the
axons. On the other hand, the amount of spin probe
used for labeling was calculated for the average total
lipid content of the myelin sheath, and since spectra
showed no spin exchange broadening, we assumed
that the signal obtained was predominantly from
the myelin sheath labeled evenly throughout.
Since the myelin sheath is structured as a multi-
layered membrane bilayer of the Schwann cell, the
recorded spectra were analyzed by a simulation
Fig. 1. Spectral components calculated by Eq. 1, used in simu-
lation of experimental spectra of spin probe MeFASL(10,3) in-
corporated into the myelin sheath lipid phase of peripheral
nerves. The components were chosen in order to meet some em-
pirical and numerical requirements explained in Section 3. The
numerical parameters for calculation of each component are
listed in Table 1.
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method developed for lipid bilayers. The recorded
spectral line shapes re£ect the microenvironment
structure and dynamics of the myelin sheath; there-
fore, the parameters used in simulation analysis al-
lowed us to estimate the £uidity of the probed myelin
structure.
According to the results of other authors obtained
on the model membranes [9,10] and our previous
results on biomembranes [11], the reasonable ¢tting
of ESR spectra at 37‡C could be made using three
spectral components. The choice of the spectral com-
ponents for our ¢tting procedure was made as fol-
lows: the parameters for the most ordered compo-
nent (I) were obtained by adjusting the outer
hyper¢ne splitting in control sample spectra, while
the parameters for the most £uid component (III)
were taken from the simulation of the inner hyper¢ne
splitting of the homogenized control samples’ spec-
tra. The ¢tting parameters for intermediate spectral
component (II) were deduced from the minimization
of the M2-value in the control spectra. Once the com-
ponents were de¢ned (Fig. 1), the parameters were
kept constant (Table 1), and weighting factors
changed in order to produce the best possible ¢t in
terms of the minimal M2-value.
Fig. 2. Experimental and simulated ESR spectra of of spin
probe MeFASL(10,3) incorporated into the myelin sheath lipid
phase of peripheral nerves. All spectra were taken at 37‡C.
Weighting factors (expressed as percentage) of the components
are indicated. (a) control spectrum, (b) spectrum taken from
sciatic nerve of diabetic rat (c) spectrum taken from sciatic
nerve of the animal that developed strong diabetic symptoms.
The simulation had to be performed employing ¢ve spectral
components with order parameters S3 of 0.64, 0.52, 0.38, 0.3
and 0.05 with rotational correlation times d20 in the range of
1.2 to 0.8 ns. (d) spectrum of EB-treated nerve.
Fig. 3. Weighting factors for spectral components obtained in
the simulation of experimental spectra of spin probe Me-
FASL(10,3) incorporated into the myelin sheath lipid phase of
peripheral nerves. Weighting factors of spectral components di-
rectly relate to the proportion of the spin-labeled molecules
that are probing structurally and dynamically di¡erent environ-
ments in the myelin sheath. Presented are the mean values
þ S.E.M. with the number of samples as follows: N(control) =
12, N(SZT-induced diabetes) = 20, N(EB) = 5. Spectra were
taken at 37‡C. Statistical signi¢cance for the comparison to the
control value is indicated by *(P6 0,05).
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3.2. ESR spectra of diabetic animals’ myelin sheath
The values of weighting factors did not di¡er sig-
ni¢cantly for the samples obtained from the same
animal, not within the control, nor within the dia-
betic group. However, the weighting factors of the
component II in the spectra of samples from diabetic
rats had signi¢cantly elevated values in comparison
to the corresponding controls (Figs. 2 and 3). This
result suggests an increase in the number of the mol-
ecules that sensed less restricted movement, and
therefore indicates an increase in the overall £uidity
of the myelin sheath. Interestingly, the samples taken
from two animals that had had very pronounced
diabetic symptoms, appeared all to have spectral
component II ‘split’ in the whole range of compo-
nents of gradually diminishing order and dynamic
parameters, indicating a decrease in overall order
of the myelin sheath lipid phase (Fig. 2c).
3.3. ESR spectra of EB-treated myelin sheath
ESR spectra of EB-treated sciatic nerves showed
qualitatively the same kind of change as did the
nerves isolated from diabetic animals (Fig. 2).
Namely, the spectra could be ¢tted with the same
three components as controls (with the notion that
these controls were not altered with respect to other
control spectra), but with increased weight of spec-
tral component II (Table 2).
3.4. ESR spectra of trypsin-treated myelin sheath
In vitro trypsin-treated sciatic nerves showed
markedly another type of £uidity change. The spec-
tra could not be satisfactorily ¢tted by the compo-
nents used in spectral analysis of control spectra, as
long as the order parameters were not signi¢cantly
decreased: in spectral component I for 10%, and in
spectral component II for 33% (Table 2).
Additionally, the weight of component III had to
be increased (for 25%) in order to produce a reason-
ably good ¢t. This type of £uidity change suggests a
signi¢cant decrease of order in the myelin sheath
under the proteolytic action of trypsin, which is an-
other type of change compared to one produced by
EB.
3.5. ESR spectra of myelin sheath under changed
osmotic conditions
Although one can expect the change of lipid phase
ordering and dynamics under changed osmotic con-
ditions, by the method applied we could not detect
any di¡erence with respect to control spectra, either
in hypo-osmotic nor in hyper-osmotic conditions.
4. Discussion
In this work we applied ESR spectroscopy to the
Table 1
The parameters for spectral components used in simulation of experimental spectra of spin probe MeFASL (10,3) incorporated in the
myelin sheath lipid phase of peripheral nerves
Spectral components Order parameters Rot. corr. times (ns)
S3 S1 d20 d22
I 0.62 30.3 1.4 3
II 0.50^0.54 30.2 1.2 2
III 0.05^0.1 0 0.6^0.8 0.6^0.8
The parameters listed were the same for spectra obtained from control animals, rats with SZT-induced diabetes, and EB-treated
nerves.
Table 2
Spectral parameters used in simulation of experimental spectra
obtained on trypsin-treated samples
Spectral
components
Order
parameters
Rot. corr.
times (ns)
Weighting
factors
S3 S1 d20 d22
I 0.56 30.2 1.4 5 0.50 þ 0.08
II 0.36 30.15 1.2 5 0.31 þ 0.03
III 0.05 0 0.8 0.8 0.18 þ 0.08
Weighting factors for spectral components are presented as
mean values þ S.E.M. for 11 spectra. Spectra were taken at
37‡C.
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spin-labeled myelin sheath lipid phase in order to at
least partially answer frequent questions on subtle
changes of myelin structure in the pathology of pe-
ripheral neuropathy in diabetes [12]. As a model we
chose peripheral nerves of rats with SZT-induced
diabetes [13], in which the peripheral neuropathy is
still questioned [14], although it develops early func-
tional and biochemical defects but with very mild (or
no) morphological changes in the peripheral nerves
[15^17].
The method of ESR with a lipophilic spin probe
evenly incorporated into the myelin structure enables
recording the spectra, containing information on the
structure and dynamics of lipid phase. Even though
the method of ESR on the spin-labeled myelin sheath
is perturbing the system by insertion of spin probe
molecules, the probed environment is practical-
ly intact in all other respects, so the method ap-
plied is non-invasive and non-destructive biologi-
cally.
The spectra of the spin-labeled myelin sheath ap-
peared to be complex (as expected for the heteroge-
neous lipid structure) and concomitantly were ana-
lyzed by numerical simulation using three spectral
components, distinguished predominantly through
di¡erent order parameters. The choice of compo-
nents was made in order to meet some empirical
(outer and inner hyper¢ne splitting) and numerical
(optimization of calculated spectra) requirements.
For the control spectra, spectral components I and
II were de¢ned by relatively high values of order
parameters. Together with their summed relative
proportions of almost 90% (Fig. 3), we could give
the ¢rst estimate of the myelin lipid phase as a highly
ordered structure, the result being in accordance with
previous experimental ¢ndings [18]. The estimate of
the myelin sheath lipid phase as a highly ordered
structure could be, at least partially, explained by
the lipid composition of myelin itself. Namely, a
high content of cholesterol (which structurally inserts
between acyl chains of phospholipids) and glycolip-
ids (which are proposed to have weak interactions
through carbohydrates) suggest an ordered structure
in the plane probed by our spin probe. On the other
hand, myelin proteins are suggested to interact pre-
dominantly with anionic lipids; myelin basic protein
is proposed to be peripherally bound to anionic
phospholipids via electrostatic interactions [19] and
proteolipids as integral proteins have strong selective
a⁄nity for anionic lipids [20]. Since cholesterol, gly-
colipids and anionic phospholipids represent approx-
imately 90% of total myelin lipid content, we suggest
that our spectral components I and II predominantly
originate from the regions populated by these lipid
classes.
The comparative analysis of results on control and
diabetic samples showed that the fraction of the
spectral component II is signi¢cantly increased in
the spectra taken from nerve samples of diabetic
rats (Figs. 2 and 3). The result suggests the increase
in the number of lipid molecules situated in a less
ordered environment, or in other words, an increase
of the average lipid phase £uidity. The origin of such
a £uidity change was tested through some simple
models: (a) experimental model for demyelination
(locally treated nerve ¢ber with EB in vivo), (b) pro-
teolytic action of trypsin on the nerve ¢ber in vitro,
and (c) changed osmotic conditions for the nerve
¢ber in vitro. The ESR spectral analysis of EB-
treated nerves show the structural and dynamical
characteristics similar to the changes seen in spectra
of diabetic samples (Figs. 2 and 3). Since the EB
treatment promotes ultrastructural changes of myelin
sheath very similar to demyelinating change in dia-
betes [21], the similarity of ESR results con¢rms the
suitability of the method applied. On the other hand,
the proteolytic action of trypsin produced £uidity
changes of di¡erent quality in the myelin sheath lipid
phase with respect to the controls; the increased
myelin sheath £uidity was expressed through signif-
icant lowering of order parameter values, with
the increased relative proportion of spectral compo-
nent III (Table 2), most probably being the conse-
quence of altered lipid^protein and protein^protein
interactions responsible for intralayer structuring.
The changed osmotic conditions, either hyper-
osmotic or hypo-osmotic, produced no signi¢cant
alterations in the sense of ESR simulation param-
eters.
In spite of the fact that this work needs additional
research, let us propose a possible mechanism that
could explain our results. The relative increase in
proportion of spectral component II (and concomi-
tant decrease in proportion of spectral component I)
suggests lipid phase order disturbance. Although the
pathological conditions of diabetes, especially hyper-
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glycemia, could be the origin of such a result, the
increased £uidity could be simply produced via the
changed lipid composition of the myelin sheath in
diabetic rats with respect to the non-pathological
myelin. This hypothesis is supported by the results
obtained on EB-treated nerves knowing that the EB
toxicity is primarily targeted to Schwann cell metab-
olism. On the other hand, the proteolytic action of
trypsin on non-pathological myelin produced in-
creased £uidity, but of di¡erent quality, probably
as a consequence of altered lipid^protein and/or pro-
tein^protein interactions, responsible for lipid phase
structure ordering. Additional support of our hy-
pothesis for changed myelin lipid composition in
pathology of diabetes, comes from very recent and
similar ¢ndings on myelin sheath isolated from ga-
lactocerebroside- and sulfatide-de¢cient mice nerves
which are associated with severe neurological de¢cits
[18]. Altered lipid composition was clearly correlated
with changed biophysical properties (such as in-
creased £uidity), suggesting that changes of biophys-
ical properties of myelin sheath could indicate a com-
mon marker and the ¢rst step in development of
di¡erent neuropathies. In addition, there are reports
on changed human sciatic nerve phospholipid pro-
¢les in diabetes [22], so the possible change in lipid
composition in case of SZT-induced diabetes in rats
(already suggested from results obtained by X-ray
di¡raction on myelin sheath [23], would suitably ex-
plain the result of changed myelin lipid phase £uidity
reported here.
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